RV1729 - single and repeat doses;version 1

• Research type

  Research Study

• Full title

  A randomised, double blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of treatment with single and repeat doses of inhaled RV1729 in healthy subjects for up to 28 days and subjects with stable asthma for 14 days (HMR code: 14-003)

• IRAS ID

  152609

• Contact name

  Adeep Puri

• Contact email

  vparker@hmrlondon.com

• Sponsor organisation

  Respivert

• Eudract number

  2014-000090-39

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  14/SC/0196

• Date of REC Opinion

  29 May 2014

• REC opinion

  Further Information Favourable Opinion